{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'The other treatment comparisons of UMEC/VI and UMEC with Salmeterol will be', 'performed on the ITT population and ITT ICS free population.', '9.4.1.', 'Primary Analyses', 'The treatment comparison of primary interest will be UMEC/VI versus UMEC for the', 'primary endpoint of change from baseline in trough FEV, at Week 24. The primary', 'analyses will be performed using a mixed model repeated measures (MMRM) analysis', 'and will be based on a two-sided hypothesis testing approach on the ITT Population.', 'In order to account for multiplicity across treatment comparisons and endpoints, a step-', 'down closed testing procedure will be applied whereby inference for secondary and other', 'endpoints or treatment comparisons are dependent upon statistical significance having', 'been achieved for the primary comparison. If the primary comparison is significant i.e.', 'the associated p-value for UMEC/VI versus UMEC for change from baseline in trough', 'FEV1 at Week 24 is below 0.05, this will allow inference of treatment comparisons', '(UMEC/VI versus UMEC on all other endpoints, and UMEC/VI versus Salmeterol and', 'UMEC versus Salmeterol on all endpoints including the primary endpoint), which will be', 'declared statistically significant if the associated p-value is below 0.05.', 'There will be 2 analyses one for one for the German Federal Joint Committee (G-BA)', 'and one for the rest of the world (ROW).', 'The step-down closed testing procedure only applies to the ROW. For the G-BA', 'statistical inference for secondary and other endpoints or treatment comparisons will not', 'be conditional on achieving statistical significance of the primary comparison.', 'The primary endpoint of mean change from baseline in trough FEV1 at the end of Week', '24 and secondary endpoint change from baseline in TDI score at Week 24 will both be', 'analysed using MMRM analysis. The MMRM analysis for change from baseline in', 'trough FEV1 and TDI will include measurements at Treatment Weeks 4, 12 and 24.', 'Treatment group (a categorical variable) will be fitted as the explanatory variable with', 'appropriate pre-defined variables, stratum (number of bronchodilators per day during', 'run-in) and baseline values, fitted as covariates. Visit (nominal) will be fitted as a', 'categorical variable and visit-by-baseline and visit-by-treatment interaction terms will be', 'included to allow treatment effects to be estimated at each visit separately. The variance', 'covariance matrix will be assumed to be unstructured (based on previous experience no', 'issues are expected with fitting models with this matrix structure).', 'While missing data are not explicitly imputed in the primary MMRM analyses, there is', 'an underlying assumption that the data are missing at random.', 'The estimated treatment differences between UMEC/VI versus UMEC for each endpoint', 'will be presented with the 95% confidence intervals for the difference and the p-value.', 'Full details of the analyses to be performed on all primary endpoints will be given in the', 'RAP.', '59']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '9.4.2.', 'Other Analyses', 'The MMRM analysis will be repeated for the ITT ICS free population. Estimated', 'differences between UMEC/VI or UMEC and Salmeterol will be presented together with', '95% confidence intervals (CIs) for the difference and p-values.', 'Secondary and other efficacy endpoints and treatment comparisons will be adjusted for', 'multiplicity as per Section 9.4.1.', 'Full details of the analyses to be performed on the other efficacy endpoints will be given', 'in the RAP.', 'Safety Analyses', 'Adverse events (AEs) will be coded using the standard GSK dictionary, Medical', 'Dictionary for Regulatory Activities (MedDRA), and grouped by body system. The', 'number and percentage of subjects experiencing at least one AE of any type, AEs within', 'each body system and AEs within each preferred term will be presented for each', 'treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal', 'AEs, non-fatal SAEs, AESIs and AEs leading to withdrawal.', 'Deaths and SAEs will be documented in case narrative format.', 'Full details of the analyses to be performed on all safety endpoints will be given in the', 'RAP.', '10.', 'STUDY GOVERNANCE CONSIDERATIONS', '10.1.', 'Posting of Information on Publicly Available Clinical Trial', 'Registers', 'Study information from this protocol will be posted on publicly available clinical trial', 'registers before enrollment of subjects begins.', '10.2.', 'Regulatory and Ethical Considerations, Including the', 'Informed Consent Process', 'Prior to initiation of a site, GSK will obtain favourable opinion/approval from the', 'appropriate regulatory agency to conduct the study in accordance with ICH Good Clinical', 'Practice (GCP) and applicable country-specific regulatory requirements.', 'The study will be conducted in accordance with all applicable regulatory requirements,', 'and with GSK policy.', 'The study will also be conducted in accordance with ICH Good Clinical Practice (GCP),', 'all applicable subject privacy requirements, and the guiding principles of the current', 'version of the Declaration of Helsinki. This includes, but is not limited to, the following:', '60']\n\n###\n\n", "completion": "END"}